BENGALURU (Reuters) – Abbott India, the Indian arm of U.S. healthcare firm Abbott Laboratories, reported a 41% rise in its first-quarter profit on Wednesday, driven by strong sales in its mainstay pharmaceuticals segment.
The company, which makes pain-reliever ibuprofen under the brand name Brufen, said its profit rose to 2.90 billion rupees ($35.02 million), compared with 2.06 billion rupees a year earlier.
Revenue from operations rose 13.4% to 14.79 billion rupees for the quarter.
For further earnings highlights, click here.
Abbott India, for which the pharmaceutical segment is the sole revenue generator, develops and distributes over 600 products in India, including vitamins, anti-allergic drugs and consumer care.
The company has reported a double-digit growth in its revenue for the past three quarters, led by falling operating expenses and steady sales.
Last month, peer GlaxoSmithKline Pharmaceuticals posted an 11% rise in its first-quarter profit, helped by a steady vaccines business.
Valuation (next Estimates (next 12 Analysts’ sentiment
12 months) months)
RIC PE EV/EBITDA Revenue Profit Mean # of Stock to Div
growth growth rating* analysts price yield
Abbott India Ltd 44.63 32.59 13.06 14.87 Buy 7 1.06 0.76
GlaxoSmithKline 37.12 26.54 5.72 4.93 Buy 6 0.98 2.28
Pfizer Ltd 27.24 18.29 6.85 5.45 Strong 5 0.87 0.89
Cipla Ltd 24.69 15.76 10.82 19.32 Buy 38 1.09 0.67
* Mean of analysts’ ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
** Ratio of the stock’s last close to analysts’ mean price target; a ratio above 1 means the stock is trading above the PT
APRIL TO JUNE STOCK PERFORMANCE
— All data from Refinitiv
— $1 = 82.8150 Indian rupees
(Reporting by Kashish Tandon and Biplob Kumar Das in Bengaluru; Editing by Janane Venkatraman)